|
[1] FORNER A,REIG M,BRUIX J. Hepatocellular carcinoma[J].Lancet,2018,391(10127):1301-1314.
|
|
[2] NIU L,LIU L,YANG S,et al. New insights into sorafenib resistance in hepatocellular carcinoma:Responsible mechanisms and promising strategies[J]. Biochim Biophys Acta Rev Cancer,2017,1868(2):564-570.
|
|
[3] LLOVET JM,PEA CE,LATHIA CD,et al. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma[J]. Clin Cancer Res,2012,18(8):2290-300.
|
|
[4] GADALETA-CALDAROLA G,INFUSINO S,DIVELLA R,et al. Sorafenib:10 years after the first pivotal trial[J]. Future Oncol,2015,11(13):1863-1880.
|
|
[5] DHANASEKARAN R,NAULT JC,ROBERTS LR,et al. Genomic medicine and implications for hepatocellular carcinoma prevention and therapy[J]. Gastroenterology,2019,156(2):492-509.
|
|
[6] YANG M,QI XS,HAN GH. Sorafenib-related adverse events in treatment of hepatocellular carcinoma[J]. J Clin Hepatol,2014,30(3):278-281.(in Chinese)杨曼,祁兴顺,韩国宏.索拉菲尼在肝癌治疗中的不良反应[J].临床肝胆病杂志,2014,30(3):278-281.
|
|
[7] ZHU YJ,ZHENG B,WANG HY,et al. New knowledge of the mechanisms of sorafenib resistance in liver cancer[J]. Acta Pharmacol Sin,2017,38(5):614-622.
|
|
[8] FRICKER M,TOLKOVSKY AM,BORUTAITE V,et al. Neuronal cell death[J]. Physiol Rev,2018,98(2):813-880.
|
|
[9] DOLMA S,LESSNICK SL,HAHN WC,et al. Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells[J].Cancer Cell,2003,3(3):285-296.
|
|
[10] YANG WS,STOCKWELL BR. Synthetic lethal screening identifies compounds activating iron-dependent,nonapoptotic cell death in oncogenic-RAS-harboring cancer cells[J]. Chem Biol,2008,15(3):234-245.
|
|
[11] DIXON SJ,LEMBERG KM,Lamprecht MR,et al. Ferroptosis:An iron-dependent form of nonapoptotic cell death[J]. Cell,2012,149(5):1060-1072.
|
|
[12] XIE Y,HOU W,SONG X,et al. Ferroptosis:Process and function[J]. Cell Death Differ,2016,23(3):369-379.
|
|
[13] KANG R,ZHU S,ZEH HJ,et al. BECN1 is a new driver of ferroptosis[J]. Autophagy,2018,14(12):2173-2175.
|
|
[14] BOGDAN AR,MIYAZAWA M,HASHIMOTO K,et al. Regulators of iron homeostasis:New players in metabolism, cell death,and disease[J]. Trends Biochem Sci,2016,41(3):274-286.
|
|
[15] ZHOU B,LIU J,KANG R,et al. Ferroptosis is a type of autophagy-dependent cell death[J]. Semin Cancer Biol,2019.[Epub ahead of print]
|
|
[16] ZOU Y,PALTE MJ,DEIK AA,et al. A GPX4-dependent cancer cell state underlies the clear-cell morphology and confers sensitivity to ferroptosis[J]. Nat Commun,2019,10(1):1617.
|
|
[17] SONG X,ZHU S,CHEN P,et al. AMPK-mediated BECN1phosphorylation promotes ferroptosis by directly blocking system Xc-activity[J]. Curr Biol,2018,28(15):2388-2399.e5.
|
|
[18] DOLL S,PRONETH B,TYURINA YY,et al. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition[J].Nat Chem Biol,2017,13(1):91-98.
|
|
[19] MOU Y,WANG J,WU J,et al. Ferroptosis,a new form of cell death:Opportunities and challenges in cancer[J]. J Hematol Oncol,2019,12(1):34.
|
|
[20] HANGAUER MJ,VISWANATHAN VS,RYAN MJ,et al. Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition[J]. Nature,2017,551(7679):247-250.
|
|
[21] VISWANATHAN VS,RYAN MJ,DHRUV HD,et al. Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway[J]. Nature,2017,547(7664):453-457.
|
|
[22] HUANG C,YANG M,DENG J,et al. Upregulation and activation of p53 by erastin? induced reactive oxygen species contribute to cytotoxic and cytostatic effects in A549 lung cancer cells[J]. Oncol Rep,2018,40(4):2363-2370.
|
|
[23] SEHM T,RAUH M,WIENDIECK K,et al. Temozolomide toxicity operates in a xCT/SLC7a11 dependent manner and is fostered by ferroptosis[J]. Oncotarget,2016,7(46):74630-74647.
|
|
[24] YUAN H,LI X,ZHANG X,et al. CISD1 inhibits ferroptosis by protection against mitochondrial lipid peroxidation[J]. Biochem Biophys Res Commun,2016,478(2):838-844.
|
|
[25] CORIAT R,NICCO C,CHREAU C,et al. Sorafenib-induced hepatocellular carcinoma cell death depends on reactive oxygen species production in vitro and in vivo[J]. Mol Cancer Ther,2012,11(10):2284-2293.
|
|
[26] LOUANDRE C,EZZOUKHRY Z,GODIN C,et al. Iron-dependent cell death of hepatocellular carcinoma cells exposed to sorafenib[J]. Int J Cancer,2013,133(7):1732-1742.
|
|
[27] LOUANDRE C,MARCQ I,BOUHLAL H,et al. The retinoblastoma(Rb)protein regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma cells[J]. Cancer Lett,2015,356(2 Pt B):971-977.
|
|
[28] SAUZAY C,LOUANDRE C,BODEAU S,et al. Protein biosynthesis,a target of sorafenib,interferes with the unfolded protein response(UPR)and ferroptosis in hepatocellular carcinoma cells[J]. Oncotarget,2018,9(9):8400-8414.
|
|
[29] BAI T,WANG S,ZHAO Y,et al. Haloperidol,a sigma receptor 1 antagonist,promotes ferroptosis in hepatocellular carcinoma cells[J]. Biochem Biophys Res Commun,2017,491(4):919-925.
|
|
[30] WANG W,GREEN M,CHOI JE,et al. CD8+T cells regulate tumour ferroptosis during cancer immunotherapy[J]. Nature,2019,569(7755):270-274.
|
|
[31] SUN X,NIU X,CHEN R,et al. Metallothionein-1G facilitates sorafenib resistance through inhibition of ferroptosis[J]. Hepatology,2016,64(2):488-500.
|
|
[32] MELOUGH MM,SUN X,CHUN OK. The role of AOPP in age-related bone loss and the potential benefits of berry anthocyanins[J]. Nutrients,2017,9(7). pii:E789.
|
|
[33] KRIZKOVA S,KEPINSKA M,EMRI G,et al. An insight into the complex roles of metallothioneins in malignant diseases with emphasis on(sub)isoforms/isoforms and epigenetics phenomena[J]. Pharmacol Ther,2018,183:90-117.
|
|
[34] SUN X,NIU X,CHEN R,et al. Metallothionein-1G facilitates sorafenib resistance through inhibition of ferroptosis[J]. Hepatology,2016,64(2):488-500.
|
|
[35] LEVINE B,KROEMER G. Biological functions of autophagy genes:A disease perspective[J]. Cell,2019,176(1-2):11-42.
|
|
[36] LEVY J,TOWERS CG,THORBURN A. Targeting autophagy in cancer[J]. Nat Rev Cancer,2017,17(9):528-542.
|
|
[37] HOU W,XIE Y,SONG X,et al. Autophagy promotes ferroptosis by degradation of ferritin[J]. Autophagy,2016,12(8):1425-1428.
|
DownLoad: